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histiocytoma. Margins of excision were negative. The patient then underwent a course of systemic Paratesticular malignant fibrous histiocytoma is an adriamycin-based chemotherapy. Further workup extremely rare malignancy of the scrotum. This via ultrasound revealed a 1.1 cm hypoechoic lesion, malignancy has rarely been described in the which was contiguous with the right testicle. The literature and scant information exists on the optimal patient then underwent a right radical orchiectomy management of this cancer. We present here a case in November of 2005 with re-excision of his prior of a 57-year-old man with a diagnosis of high-grade surgical scar. Pathology was entirely negative for malignant fibrous histiocytoma of the left intrascrotal residual sarcoma. The patient then presented for a region who underwent radical orchiectomy, systemic course of postoperative radiotherapy. chemotherapy and postoperative radiotherapy.
The patient was treated with a course of externalbeam radiotherapy to the pelvis delivered in an AP/
INTRODUCTION CASE REPORT
A 57-year-old gentleman who presented with a diagnosis of high-grade paratesticular malignant fibrous histiocytoma. He originally presented with a left undescended testicle. In 1979, he underwent a left orchiectomy. He had an uneventful genitourinary history until 1996 when he presented with a left intrascrotal mass. This mass was gross totally excised and pathology revealed benign lipoma.
He was without evidence of disease until February of 2005. At that time, the patient noted a left-sided intrascrotal mass. His primary care physician confirmed this finding and an ultrasound revealed a 1.4 cm solid lesion in the left scrotum. In June of 2005, the patient presented for resection of this lesion. Pathology showed a 5.1 x 4.9 x 3.6 cm mass consistent with high-grade malignant fibrous PA fashion with the inguinal lymph nodes inclusive. 6 MV photons were delivered from the anterior field and 15 MV photons were delivered from the posterior field. The radiation dose was calculated from the posterior exit beam to delineate dose delivered to the inguinal nodes. Then, customized electron cutouts were designed to bring the dose to the inguinal nodal chain to 100% of the prescribed dose. 9 MeV electrons were utilized. Depth of the inguinal nodes was calculated from the treatment planning CT scan.
By 1440 cGy, the patient developed some mild groin redness. By 2520 cGy, he developed groin erythema and discomfort and was given Tylenol #3 in addition to topical ointments. At 3060 cGy, the patient developed a tinea infection of the groin and was subsequently placed on an anti-fungal regimen. At this juncture, the patient also required a significant radiation therapy break, secondary to moist groin desquamation and discomfort. In addition, penile erythema and discomfort were noted. The patient was prescribed a course of Silvadine cream to be applied to the affected areas while on break. Upon return to clinic, the patient experienced near total re-epithelialization and resolution of his groin and penile erythema. He completed a dose of 4500 cGy without further difficulty. However, the radiotherapy had to be discontinued at 3800 cGy secondary to abscess formation and decubitus around the silicone wrapped testicle. The patient was followed for 30 months following surgery with no evidence of tumor recurrence. [3] These three studies illustrate the importance of adjuvant therapy to the management and prevention of recurrence of intrascrotal sarcoma. Furthermore, the Princess Margaret up.
patient elected to forgo any subsequent boost and treatment Hospital review demonstrates the need for adjuvant therapy was discontinued at 4500 cGy. At one month, follow-up, the to the groin to prevent relapse in these patients. patient demonstrated no evidence of malignancy and near-full resolution of treatment side effects. Additionally, axial computed Additionally, Froehner and colleagues reviewed 22 cases of tomography scans of the abdomen and pelvis, respectively, locally recurrent malignant fibrous histiocytoma and found the showing absence of malignant adenopathy at six weeks followprognosis for these patients to be extraordinarily poor. Only two of 22 patients survived past 3.5 years of follow-up. This study demonstrates the need for proper multi-modality DISCUSSION treatment of patients presenting with primary malignant fibrous histiocytoma so as to avoid the morbidity that This case critically underscores the difficulty in managing accompanies local recurrence. [4] malignancies requiring pelvic and inguinal nodal radiotherapy and their attendant side-effects. Paratesticular sarcomas are This case of scrotal malignant fibrous histiocytoma illustrates an extremely rare entity and a paucity of information about the critical importance of adequate primary and adjuvant their management exists in the literature. Fagundes, et al management as well as proper radiation therapy technique. analyzed 18 patients with this disease entity from the Also, critically important is the meticulous care of the patient Massachusetts General Hospital. 16 patients underwent radical during radiotherapy as adjuvant radiation therapy is often not orchiectomy, while all 18 underwent surgical resection. Nine of without significant side effects in this anatomic site. Intensity the 18 patients received adjuvant radiotherapy coupled with modulated radiation therapy, as well as conformal therapies, orchiectomy, while the remaining nine patients received surgery may play a role in managing this difficult entity in the future. alone. Five of the nine patients treated with orchiectomy alone Further retrospective reviews and, possibly, prospective trials developed locoregional recurrence, while no patient who are warranted to more fully elucidate the optimal management received adjuvant radiotherapy relapsed. The median radiation of this rare malignancy. dose was 4500 cGy. [1] 
